Vor Biopharma appointed Andrew Levin from RA Capital and Wouter Joustra from Forbion to its Board of Directors, strengthening its leadership in autoimmune disease treatment.
RemeGen's Telitacicept for gMG to be presented at AANEM
RemeGen's Telitacicept 48-week OLE data for gMG treatment to be presented at AANEM 2025. Vor Bio advancing global Phase III trials for Telitacicept in gMG.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.